Study S001945

Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07590219
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 30
Start: 2024-03-30
Primary completion: 2027-04
Lead sponsor: University of Sao Paulo General Hospital
Conditions: Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking
Interventions: DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Results posted: FALSE

Registered primary outcomes

Change in Body Mass Index (BMI) [6 months]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009964	Once-Weekly Semaglutide in Adolescents with Obesity. Weghuber D, The New England journal of medicine	2022	Randomized trial	PMID 36322838 DOI	registry reference BACKGROUND:36322838
R0023922	A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. Kelly AS, The New England journal of medicine	2020	Randomized trial	PMID 32233338 DOI	registry reference BACKGROUND:32233338
R0022060	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27295427 DOI	registry reference BACKGROUND:27295427
R0021011	Incretin-based therapies: viewpoints on the way to consensus. Nauck MA, Diabetes care	2009	Narrative review	PMID 19875556 DOI	registry reference BACKGROUND:19875556